Ipamorelin: Frequently Asked Questions
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Why is ipamorelin considered the most selective growth hormone secretagogue?
Ipamorelin's selectivity was established in the 1999 Raun et al. study, which showed it released GH potently while producing no significant changes in cortisol, ACTH, prolactin, FSH, or LH, even at doses 500-fold above the GH-releasing threshold (PMID: 10580762). Older GHRPs like GHRP-2 and GHRP-6 elevate cortisol and prolactin in a dose-dependent manner. Cortisol elevation is a significant practical concern with long-term use because chronically elevated cortisol promotes fat storage, muscle breakdown, and disrupts sleep. Ipamorelin's receptor binding profile produces the desired GH output without these hormonal side effects.
Why is ipamorelin usually stacked with CJC-1295?
Ipamorelin and CJC-1295 act on two different receptors: ipamorelin on the ghrelin receptor (GHS-R1a) and CJC-1295 on the GHRH receptor. When both pathways are activated simultaneously, GH output is substantially greater than either compound alone. Research on GHRH + GHRP combinations shows approximately 3-fold greater pulsatile GH secretion than either agent alone (PMID: 9849822). The combination is also practical: CJC-1295 without DAC can be mixed in the same syringe as ipamorelin for a single injection. Most anti-aging telehealth protocols prescribe them together for this reason.
How does ipamorelin differ from GHRP-2 and GHRP-6?
All three are GHRPs that work through the ghrelin receptor, but ipamorelin is far more selective. GHRP-2 is the most potent of the three for raw GH release but significantly elevates cortisol and prolactin. GHRP-6 produces strong appetite stimulation that many users find unmanageable, along with moderate cortisol and prolactin increases. Ipamorelin releases GH at comparable potency to the others while producing negligible effects on cortisol, prolactin, and appetite (PMID: 10580762). For long-term use in healthy adults seeking anti-aging or body composition benefits, ipamorelin's cleaner hormonal profile makes it the preferred option.
What results can I expect from ipamorelin?
Clinical and community data suggest a typical progression. Sleep quality improvement (deeper sleep, more vivid dreams) is usually the earliest change, often within 1-2 weeks. Improved recovery from exercise appears at 2-4 weeks. Visible body composition changes, including modest lean mass increase and reduction in abdominal fat, typically require 8-12 weeks of consistent use. GH secretagogue reviews confirm the class improves body composition and IGF-1 levels while maintaining physiologic hormone ranges (PMID: 32257855). Results are notably more subtle than direct HGH and are best assessed through baseline and follow-up IGF-1 blood testing.
Is ipamorelin legal in 2026?
Ipamorelin's legal status has been in flux. The FDA placed it on the Category 2 bulk drug substance list in 2023, effectively prohibiting licensed compounding pharmacies from producing it. In February 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 restricted peptides would return to legal compounding status, though the specific official list had not been published at that time. Ipamorelin is not a controlled substance. Outside of compounding pharmacy channels, it is available as a research chemical from non-pharmacy vendors, which is unregulated and carries different risk considerations. Consulting a licensed physician is the appropriate path for medical use.
Sources
- Ipamorelin, the first selective growth hormone secretagogue — European Journal of Endocrinology (1999) [PubMed]
- Growth hormone secretagogues: history, mechanism of action, and clinical development — JCSM Rapid Communications (2017) [PubMed]
- The effects of growth hormone-releasing peptide-6 and growth hormone-releasing hormone on the pulsatile growth hormone secretion in normal adult men — Journal of Clinical Endocrinology & Metabolism (1999) [PubMed]
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational Andrology and Urology (2020) [PubMed]
- The Safety and Efficacy of Growth Hormone Secretagogues — Sexual Medicine Reviews (2018) [PubMed]
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.